1027385-05-2

Upstream product

• 1082937-30-1 [(R)-3-(4-cyanophenylamino)-2-hydroxy-propyl]carbamic acid tert-butyl ester 
• 1082937-32-3 [(S)-3-(4-cyanophenyl)-2-oxo-oxazolidin-5-ylmethyl]-carbamic acid tert-butyl ester 
• 1261131-68-3 4-(3-(1,3-dioxoisoindolin-2-yl)-2-hydroxypropylamino)benzonitrile 
• 1261131-70-7 (S)-4-(5-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxooxazolidin-3-yl)benzonitrile 
• 24065-33-6 5-Chlorothiophene-2-carboxylic acid 
• 1082937-34-5 (S)-4-(5-(aminomethyl)-2-oxooxazolidin-3-yl)benzonitrile 
• 873-74-5 4-Aminobenzonitrile 
• 1159610-74-8 boc 

Downstream Products

• 1082936-38-6 5-chlorothiophene-2-carboxylic acid {(S)-3-[4-(4,5-dihydro-1H-imidazol-2-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}amide 
• 1159610-47-5 C₂₁H₂₂ClN₅O₃S 
• 1159610-21-5 (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide 
• 1082936-48-8 5-chlorothiophene-2-carboxylic acid {(S)-3-[4-(1-methanesulfonyl-4,5-dihydro-1H-imidazole-2-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}amide 
• 1082936-46-6 5-chlorothiophene-2-carboxylic acid {(S)-3-[4-(1-acetyl-4,5-dihydro-1H-imidazole-2-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}amide 

Relevant academic research and scientific papers

Design, synthesis and structure - activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors

Abstract A novel series of potent and efficacious factor Xa inhibitors which possesses pyrrole/indole/thiazole moieties as S4 binding element was identified. Compound 7b showed strong human factor Xa inhibitory activity (IC50 = 2.01 nM) and ant

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES

Provided is a method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives of Formula (I) which are useful as blood coagulation factor Xa inhibitors, and said metho

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic araidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof, and processes for preparing the same, and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof can be usefully employed as an anticoagulant for treating thromboembolism and tumors via inhibition of coagulation factor Xa.